Showing papers by "Hidefumi Higashi published in 1987"
TL;DR: Endoscopic injection sclerotherapy was given to 155 patients with esophageal varices mainly related to non‐alcoholic liver cirrhosis, with the formation of a superficial ulcer in the lower esophagus achieved in 141 of the 155 patients.
116 citations
Journal Article•
TL;DR: It is concluded that 5% ethanolamine oleate seems to be superior to 1% Aethoxysklerol when used for sclerosing esophageal varices in endoscopic injection sclerotherapy (EIS).
Abstract: Thirty-four consecutive patients with liver cirrhosis and esophageal varices were included in a prospective randomized trial done to investigate the efficacy and safety of two sclerosants 5% ethanolamine oleate (EO) and polidocanol (1% Aethoxysklerol [AS]) for use in endoscopic injection sclerotherapy (EIS). Eighteen patients were randomly allocated to the group given EO and 16 to the AS group. These two groups were comparable with regard to age, sex, etiology and severity of the liver disease. The bleeding rate from esophageal ulcers which developed during the course of repeated EIS was significantly (P less than 0.05) higher in the AS group (31.3%, 5/16) than in the EO group (0%, 0/18). In 4 occasions bleeding from the esophageal ulcer could not be controlled with AS. In 3 of these 4 bleeding episodes, EO successfully halted bleeding from esophageal ulcer. In the other patient, a Sengstaken-Blakemore tube was inserted to stop the hemorrhage. The period and number of sessions of EIS for eradication of esophageal varices were significantly (P less than 0.05) shorter in the EO group than the AS group (EO: 4.0 +/- 0.8 [means +/- SD] sessions during 4.7 +/- 1.5 weeks versus AS: 4.8 +/- 1.2 sessions during 5.4 +/- 1.6 weeks). The rate of early mortality did not differ between the two groups. We conclude that 5% ethanolamine oleate seems to be superior to 1% Aethoxysklerol when used for sclerosing esophageal varices.
32 citations
Journal Article•
TL;DR: A 74-year-old female undergoing hepatic resection for hepatocellular carcinoma developed intrahepatic recurrence together with lung metastases 6 months later and has been on oral HCFU without any adverse effect and was well at the time of writing.
Abstract: A 74-year-old female undergoing hepatic resection for hepatocellular carcinoma developed intrahepatic recurrence together with lung metastases 6 months later. At detection of recurrence, she was treated by lipiodolization using 20 mg adriamycin by Seldinger's technic. She was then placed on oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) daily. Three months later, it was found that the numbers and size of metastatic nodules in the lungs had markedly decreased on plain chest X-ray. Hepatic angiogram also showed a decrease in the size and numbers of intrahepatic nodules. Serum concentration of alpha-fetoprotein dropped from 8,200 ng/ml at detection of recurrence to 19.1 ng/ml 9 months after initiation of HCFU therapy. She has been on oral HCFU without any adverse effect and she was well at the time of writing, 19 months and 13 months after surgery and detection of recurrence, respectively.
1 citations